9 Policy Wins For Biocom
Member Services: Responding to 13 Your Needs
LifeLines 18 STEM is the New Trend For the Southern California Life Science Community
The Forces Shaping Our Future
VOLUME 24, ISSUE 3 Fall 2015 ONE TEAM. ONE FOCUS. www.sdlifesciences.com
LILLY DEXCOM, INC. ALTHEADX 300,000 SF Tenant Representation 218,000 SF Tenant Representation 70,000 SF Tenant Representation
BRENT JACOBS [email protected] TENANT REP CA License No. 791657 GREG BISCONTI [email protected] FOR THE CA License No. 1167920
TED JACOBS LIFE SCIENCES [email protected] CA License No. 1855220 INDUSTRY. (858) 452-6500
ARCTURUS THERAPEUTICS SYNTHETIC GENOMICS BIOCOM 10,000 SF Tenant Representation 75,000 SF Tenant Representation 10,900 SF Tenant Representation
CUBIST GENOMATICA VERENIUM / BASF 45,000 SF Sublease Disposition 70,000 SF Tenant Representation 60,000 SF Tenant Representation WELCOME IN THIS ISSUE By Joe Panetta, 2 Cover Story: Five Undeniable Forces Shaping Our President and CEO, Biocom Life Science Future 9 Public Policy : Policy Wins For Biocom 10 Guest : An Intern’s Lens into the FDA WELCOME TO LIFELINES 12 Events: Biocom Launches New Speaker Series Welcome to the fall 2015 edition of LifeLines and our continuing 20th anniversary 13 Membership: Member Services: Responding to celebration of Biocom, California’s longest established life science association. Your Needs With more than 700 members supporting the life science community, I am proud to 14 Guest: Evaluating our Health Insurance Trust report that we are providing unsurpassed programs: robust advocacy at every level of 17 Biocom Institute: Never Stop Learning government; tremendous member services, including the Biocom Purchasing Group; 18 Science Festival: STEM is the New Trend and outstanding partnering opportunities. In addition, through our relationships 20 Members in Action: Biocom Events with associations in Europe, Australia and Asia, we are raising capital for Southern 25 Purchasing Group: Member Driven Evolution California. 26 Premium Member Spotlights: As we have welcomed throngs of members to our new state-of-the art-facilities on BioMed Realty, Bridge Bank, Dowling & Yahnke, Torrey Pines Mesa, we appreciate the “Ecosystem of Innovation” that exemplifies this VWR, Biocom region. I wish to personally thank all of our members – companies, research institutes, 30 Biocom Board and Committees the service sector and academia – who have so warmly welcomed us to the Torrey Pines 31 Biocom Membership Mesa. We have spent much of this anniversary year reflecting on the past: celebrating the successes, large and small, that have helped grow the Southern California life science industry into the powerhouse it is today. But in this LifeLines we are taking a decidedly forward-looking approach, asking the question: What are the forces shaping our future? We know from experience that it’s impossible to predict specifics. For example, if EDITOR: Jennifer Landress you had asked me that question in 1995, I could never have forecast the immense role genomics would play throughout the life science industry. The first human genome COPY EDITOR: Josh Baxt sequence was still years from completion. DESIGN & LAYOUT: Arlene Arreola It’s also unlikely I could have foreseen the level of innovation this region would produce in two short decades. Some of San Diego’s most groundbreaking therapeutics VOLUME 24, ISSUE 3 such as Rituxan, Viracept and Byetta had not yet been commercialized. Influential San Diego companies, such as Illumina, Nuvasive and Dexcom, had not even been founded yet. Still, while it is difficult to guess what the next 20 years will bring, we can (and do) think hard about which factors will make us stronger and better-equipped to be the global life science leader. Biocom is addressing these forces on many fronts: from having a competitive talent pool to accessing capital. Through these measures, our prowess will continue to expand in genetic sequencing, big data, manufacturing, Biocom, a member driven telemedicine and other areas. This industry is changing our world dramatically. We’ve organization, is here to assist never been more excited to see what the future will bring. life science companies like Our advocacy initiatives continue to influence policy decisions on the local, state yours to fulfill your most and federal levels. Biocom’s board believes these efforts are best served through ambitious goals. We can regional association representation in partnership with our sister associations at the help your company with saving money, advocacy, regional and federal levels. In this issue, you will learn how we have been working hard increased visibility, networking to create more opportunity for life science investment through the State of California, opportunities, capital and continuing our efforts to partner with legislative leaders, such as Congressman development and workforce Continued Pg 8 development. WWW.BIOCOM.ORG
Biocom LifeLines Fall 2015 1 COVER STORY By Kelly Quigley, Canale Communications Five Undeniable Forces Shaping Our Life Science Future From new venture funding strategies to the next generation of CEOs, here are some of the biggest factors shaping the regional life science industry in years ahead.
As Biocom closes out its 20th year with a bang, many of us are parts of the life science sector today. left pondering: What will Southern California’s life science industry But that’s not to say the industry’s success is surprising. Going look like in another two decades? back to its earliest years, Biocom anticipated the key elements What regional life science company will be capturing national that would be needed to create an environment ripe for innovation. headlines with its breakthrough technology? What will be the next For example, a life science cluster of this size simply can’t thrive blockbuster drug or life-changing medical device to emerge from without healthy government support, a rich academic infrastructure our ranks? and a diverse ecosystem of service providers. Biocom has devoted Interesting thoughts, to be sure. But given that innovation is much of its energy to ensuring that these and other essential inherently unpredictable, is it even possible to foresee the twists pieces are firmly in place. and turns that will shape the industry in the years leading to 2035? As Biocom enters its third decade of growth, we take a look If the past is any indication, the answer is probably no. at the factors shaping the sector’s evolution in the years ahead. Since its modest beginnings in the late 1970s, the Southern Although these innovations might not yet be apparent, the forces California life science industry has grown in unexpected and that will lead to their creation are already here. remarkable ways—to the point where it’s now generating a hefty $76 billion in economic activity each year. ONE Even in 1995, when Biocom was founded, it’s highly unlikely Money, money, money that anyone could have predicted the explosive growth in genomics, Let’s face it. Innovation is expensive. Capital—and lots of it— mobile health and synthetic biology, which have become critical is needed to fund research, development and commercialization
2 Biocom LifeLines Fall 2015 COVER STORY for groundbreaking life science products. If companies can’t get handling information-intensive computing for the national research money, they can’t change the world. community, explains Wayne Pfeiffer, the center’s co-founder and “As an industry, we’ve come to better understand molecular bioinformatics lead. biology and genomics, which produces even better healthcare Among the center’s many ambitious projects is the Cancer innovations,” says Carol Gallagher, Pharm.D., partner at venture Cell Map Initiative, which seeks to determine how all cancer cell capital firm New Enterprise Associates. “But even as we gain components interact. The initiative will provide infrastructure for more knowledge, I don’t think the capital intensity is ever going to the alliance between UC San Diego Health Sciences and San decrease. That’s the challenge. To continue to create innovation, Diego-based Human Longevity, which plans to generate thousands we need capital from a variety of sources—a full ecosystem of of tumor genomes from UC San Diego cancer patients. public investors, grant money and venture capital.” While the demand for such data-based healthcare applications So what’s the secret to keeping this ecosystem going? Is there a seems limitless today, things were much different when the center magic business model that will grab investors’ attention in the years started in 1985. “Our work was mainly in the physical sciences— ahead? Gallagher thinks not: “It always goes back to better therapies. chemistry, physics, astronomy,” Pfeiffer says. “Biologists were Sometimes not dealing with data at this level. And certainly not healthcare companies get professionals.” “I DON’T THINK THE CAPITAL overly focused Today, genomic data is shaping nearly every facet of life INTENSITY IS EVER GOING on how cool the sciences, from the development of new diagnostics to personalized science is and medicines. “The larger and larger the databases become, the more TO DECREASE. THAT’S THE forget about what useful they are,” Pfeiffer says. With more data, it’s easier to spot CHALLENGE.” they’re doing for patterns and make connections between biomarkers and disease. the patient.” San Diego companies, including Illumina and Edico Genome, Equally as are spearheading efforts to standardize the way genomic data is important, life science companies must communicate how their recorded and shared to maximize clinical utility. products fit into the existing healthcare system. If you have to However, from a data perspective, storing every person’s change how the system works, it’s going to be a harder sell. complete genomic profile isn’t realistic, Pfeiffer notes. Once full- Looking ahead, Gallagher wonders whether the relatively recent genome sequencing goes mainstream, it’s likely that only variants “cross-over” investing craze will stick around for the long term. will be stored—a tradeoff commonly made in other data-intensive Cross-over investing refers to would-be stock-market investors fields. funding a private company in advance of an expected initial public In the next 20 years, Pfeiffer predicts the genomic revolution offering. The model has provided added capital for promising will have conquered many high-priority diseases and become companies, giving them fuel to mature and expand. In the future, more focused will this model help create the next Amgen, Celgene or Genentech on preventative right in our own backyard? health. “Precision “PRECISION MEDICINE ISN’T “Investors are, and will continue to be, willing to pay for medicine isn’t GOING TO BE JUST FOR SICK innovation that changes lives,” Gallagher says. “It’s important to going to be just keep the engine of innovation strong; that’s what organizations like for sick people,” PEOPLE.” Biocom are designed to do.” he says. “It’s going to be helping healthy people live even longer, healthier lives.” TWO By then, perhaps the industry will already have moved on to the Even bigger data zettabyte. Say goodbye to gigabytes and terabytes, and roll out the welcome mat for our new friend, the petabyte. THREE At a million gigabytes of data, the petabyte is what the industry Consumer empowerment will increasingly need to store the reams of biological data produced Patients are increasingly knowledgeable about all things health on today’s high-powered genomic sequencing machines. care—and their voices are rightfully carrying more weight than For the folks at the San Diego Supercomputer Center at the ever. It’s a trend that’s expected to continue, leading to greater University of California, San Diego, the petabyte is nothing new. transparency and more convenience across the healthcare They’ve been dealing with that magnitude of data for some time, spectrum.
Continued Pg 5
Biocom LifeLines Fall 2015 3 Experience How Everything We Do [ Has A Single Focus - Your Success]
Focusing on private companies preparing to go public or be acquired, we provide aaest and tax services to a wide variety of public companies, early-stage and growing private companies.
We are one of San Diego’s largest Life Sciences and Technology Praccces. COVER STORY
This force is perhaps strongest in the fast-growing mobile to genomics-driven solutions to address such global challenges. health sector, where patients are proactively tracking their body’s Among its many projects is a research agreement with ExxonMobil metrics through health apps and accessing caregiver support from to develop highly anywhere that has a wireless connection. efficient algae Smartphones “are the most rapidly adopted technology in the strains that “THE LINK TO GLOBAL WARMING history of man,” writes Eric Topol, M.D., director of the Scripps convert sunlight IS NO LONGER DEBATABLE.” Translational Science Institute in San Diego, in his newest book and carbon The Patient Will See You Now. dioxide into biofuel. “If we liken the new model to the business world, the patient “The fact remains that we, as a planet, are burning more fossil becomes chief operating officer—a notable promotion from fuels every year and emitting more carbon dioxide,” Fetzer says. nobody to senior “The link to global warming is no longer debatable.” management,” Just as unmet medical needs drive biopharmaceutical innovation, “WHEN YOU START THINKING Topol observes. global sustainability challenges will continue to create a thriving IN A CONSUMER-CENTRIC WAY, Meanwhile, market for synthetic biology and biorenewables, Fetzer notes. TERMS LIKE EMPATHY, DELIGHT, government CONVENIENCE, AFFORDABILITY healthcare FIVE TAKE ON A GREATER reforms have Generation Z shifted towards Forbes calls them rebels with a cause. Entrepreneur says they’re SIGNIFICANCE.” outcomes-based realists with an entrepreneurial edge. But it’s all speculation at reimbursement this point, as the youngest members of Generation Z are still in models, demanding an additional level of reporting on the patient elementary school. experience. One thing is certain: In 20 years, Generation Z will have made “When you start thinking about healthcare in a consumer-centric its presence known in Southern California life science. They way, terms like empathy, delight, convenience and affordability will be the next crop of scientists, marketers, CEOs and venture take on a greater significance,” says Nina Kjellson, general partner capitalists. And the most successful companies will be doing all the at venture capital firm Canaan Partners, which is active in Southern right things to attract and retain the best of this new generation— California healthcare IT. “Even life science companies need to be rethinking company culture and providing an environment in which thinking about this because increasingly, innovative products will they’ll want to stay and prosper. be judged not only on safety and efficacy but also on consumer Along with compensation and leadership opportunities, companies engagement.” will need to create a physical space that speaks to new generations, notes Tracy Murphy, regional vice president of BioMed Realty Trust FOUR in San Diego. The workspace must evolve to meet a growing desire to Sustainability blend hard work By 2035, the world population will have grown to more than with inspiring 8 billion and life expectancy will be even longer than it is today. diversion. “ACCESS TO RESTAURANTS AND More people will require our planet’s limited resources for a longer “Access to SHOPPING IN A MORE CAMPUS- amount of time. More water, more energy, more food, more goods. restaurants and LIKE ENVIRONMENT WILL Sustainability begins with an understanding that everything we shopping in a BECOME THE STANDARD DESIGN, need for our wellbeing depends, either directly or indirectly, on more campus- our natural environment. It’s the driving principle behind Southern like environment RATHER THAN THE INNOVATIVE California’s booming biorenewables sector, which features an array will become the EXCEPTION.” of companies focused on biofuels, specialty enzymes, renewable standard design, chemicals and algae research. rather than the innovative exception,” Murphy says. “Companies “When you think about the challenges we currently face in the like Google have put a spotlight on the workspace and how it can world, be it food production or our use of energy, sustainability is be open and enjoyable, where employees can work and collaborate a topic that comes up again and again,” says Oliver Fetzer, CEO of while also enjoying leisurely activities.” San Diego-based Synthetic Genomics. Adding to the sustainability trend, the new generation of life Co-founded by J. Craig Venter, Synthetic Genomics is dedicated science leaders will seek out buildings with minimal carbon
Continued Pg 6
Biocom LifeLines Fall 2015 5 COVER STORY
footprints, she adds. They’ll demand green roofs, recycled water Policy. From taxes to NIH funding, Biocom is constantly tracking for cooling and irrigation and fuel-cell technology for affordable legislation at the local, state and national levels, advocating for power. “We’re excited to see what the next 20 years will bring policies that accelerate life science innovation. because we know that the best has yet to come,” Murphy says. Kelly Quigley is content director for Canale Communications and That’s Not All… a former biotech journalist. At CanaleComm, she specializes in There’s a range of other forces that will play a leading role in thought leadership strategy and content development for life science the growth and evolution of the Southern California life science companies. industry: Water. Yes, it’s possible to get even smarter about water usage, and we will. Stem cells. Regenerative medicine is growing fast, with dozens of promising therapies at various stages of development. Cures are more than a pipe dream. Teamwork. Expect a greater level of collaboration among the life science powerhouses in San Diego, Orange County and Los Angeles as the SoCal region competes with other U.S. and international life science clusters.
Make Your Mark in BiotechnologY Professional Science Master’s The Professional Science Master’s in Biotechnology from CSUSM is a degree that leads to jobs with graduates reporting a 97% employment rate at time of graduation. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry. For more information contact us at www.csusm.edu/el/psmlifelines
HURRY! Fall 2016 Start APPLY TODAY
WELCOME CONTINUED By Joe Panetta, President and CEO, Biocom February 24-25, 2016 The Lodge at Torrey Pines Scott Peters, to protect intellectual property and successfully oppose negative Congressional legislation. THE PREMIER Biocom’s membership recruitment is at an all-time high, but we are also focused on member retention. The power of retention PARTNERING EVENT ensures that our members have a long-term investment in Biocom, that we build a network of members working together as a region and that we invest in delivering better value for all members. This year, 2016 I will personally hold more than 50 meetings with member CEOs specific to retention, and my team will hold countless more with Biocom’s 6th Annual Global Life Science Partnering company representatives. Conference is an exclusive global partnering and networking forum that brings together senior We are especially pleased that our partners at Alexandria Real executives, bankers, venture capitalists, and Estate have provided amazing meeting and presentation facilities. We business development professionals from leading can now hold a number of our events, including quarterly breakfast pharmaceutical and biotech companies. meetings, at our facility. As a result, we are launching a variety of new events, including a CFO speaker series and Fireside Chat The conference will include panel discussions on program with regional CEOs. Our first chat was a remarkably candid relevant topics with senior industry leaders, start-up and engaging discussion with Illumina CEO Jay Flatley in our on-site company presentations, one-on-one meetings, and Illumina Auditorium. I look forward to more next quarter. numerous networking opportunities. We continue to pursue strong workforce education and training programs. In this issue, we review where are they now, which highlights individuals whose life science careers have benefitted from these programs. In addition, our San Diego Festival of Science and Engineering staff discuss how STEM is the new trend in education and how the Festival is leading this movement. Finally, you will read how the Biocom Purchasing Group, which we began not long after Biocom was founded, is making a push to ensure that all of our contracts, with more than 40 vendors, are competitive on a global scale. The Purchasing Group continues to be the gold standard for the life science industry, and we are making every effort to increase its value for our members. Please enjoy this issue of LifeLines, come by and visit our beautiful new facility and engage with us as we continue to accelerate life science success in our region.
www.biocom.org PUBLIC POLICY By Jimmy Jackson, Senior Vice President of Public Policy, Biocom Policy Wins For Biocom
Policy wise, the past few months have been some of the most On the local level, Biocom has been actively involved with the eventful in Biocom’s 20-year history. As California’s oldest and County of San Diego’s working group on sharps disposal. The group most established life science association, we are proud to represent continues to review background information, including existing the broad interests of our membership. infrastructure and sharps regulations in other jurisdictions. With the state legislature adjourned, it has been a successful Biocom continues to ask the County to update its website with a year for Biocom’s state policy efforts. Only one bill Biocom comprehensive list of current take-back sites, including designated opposed, which governs consumer products, was signed into law take-back sites in the county program and private locations that by Governor Jerry Brown; however, several bills we supported were only take sharps from customers. We will continue to engage with approved, including a bill (SB 671) creating a structure by which this group. biosimilars can be substituted for their reference product. One of Finally, the Public Policy Department held two major events. the most important bills to come out of this year’s session was AB The first was a facilities workshop at the SDG&E Energy 437, which would have allowed small businesses (annual revenues Innovation Center to discuss facilities management challenges, below $5 million) to receive state grants for a percentage of their especially for people whom facility management is a small part unused R&D credits. Biocom organized a letter from its member of larger responsibilities. We also held our Biocom PAC Annual companies to Governor Brown urging him to sign this legislation – Elected Officials Reception at the beautiful Celgene campus. 46 companies signed on to this correspondence. Unfortunately, The reception attracted one of the more diverse collections of this legislation, as well as all other proposals containing a tax elected officials we have had at this event: Congressmen Darrell credit, was vetoed by the Governor on October 10. Issa and Scott Peters; State Senator Marty Block, Assemblymen Meanwhile, Congress continues to move toward its own mid-term Rocky Chavez and Brian Jones; County Supervisors Dianne Jacob adjournment. Patent reform bills (HR 9 and S 1137), which could and Dave Roberts; and, from the City of San Diego, Mayor Kevin adversely affect the life science industry, had been advancing Faulconer and Councilmembers Chris Cate, Todd Gloria, and Mark in Congress despite industry efforts to amend them. However, Kersey. Assemblywomen Lorena Gonzalez and Shirley Weber were lobbying by Biocom’s Washington DC office, in cooperation with scheduled to attend, but a Senate Appropriations Committee BIO, PhRMA, various regional life science associations and venture hearing in Sacramento ran into the evening, preventing them from capital, patient advocacy and other groups, led to the bills being making their flights. Speaker Toni Atkins was called away because withdrawn for the time being. Biocom member companies also of her work on the Special Legislative Session on Transportation weighed in on this issue with Congressional offices, using a letter and Infrastructure. We thank signature sponsor Genentech and from Biocom urging House members to oppose HR 9. host sponsor Celgene for making this event possible. In July, we responded to a letter co-authored by Congresswoman Susan Davis, which was about to be circulated. The letter asked her colleagues to advocate for a lower standard of data exclusivity in the negotiations for the Trans-Pacific Partnership (TPP) agreement Jimmy Jackson is the Senior Vice President than the 12 years that is law in the US. Biocom and CLSA teamed of Public Policy for Biocom. He oversees up immediately to generate a joint letter asking members of government affairs and public policy for the Congress not to sign on to the Blumenauer-Davis-Himes letter. organization. Partly as a result of Biocom and CLSA’s rapid response, this letter secured only eight additional co-authors (out of a possible 432). Unfortunately, the announcement was made that TPP would only guarantee eight years of data exclusivity for biologics and Biocom has communicated our disappointment to the California delegation on this decision. In addition, Biocom’s Washington office remains active on repealing the medical device tax and giving input for the Senate version of the House’s 21st Century Cures Initiative.
Biocom LifeLines Fall 2015 9 GUEST By Veronica Bradley, Student, UCSD Bioengineering
An Intern’s Lens into the FDA
In Spring of 2015, Veronica Bradley, a UCSD Bioengineering be able to make a contribution and to have so much support from the student, met Biocom CEO Joe Panetta at a Bioengineering Career Day division I worked in. The employees in the Division of Ophthalmic on campus and expressed an interest in FDA regulatory policy as a and ENT Devices (DOED) taught me so much in my time there. From career. Joe, a former EPA regulator himself, invited her to attend a lessons about the review process to details about the science behind Biocom breakfast meeting where Dr. Jeff Shuren, Director of the FDA’s specific devices, it was all fascinating and eye-opening. Center for Devices and Radiologic Health (CDRH), was to speak via I very much appreciate the opportunity I got this summer. I skype. Veronica was allowed to ask the first question, so she told discovered my own interest in regulatory work, and also realized my Shuren of her interest. He related that he had started at FDA as an preference toward the engineering testing in particular. Needless to intern and suggested she apply for their internship program. Veronica say, the internship was invaluable, and I would strongly encourage was accepted into the ten week internship program, and our budding those in my discipline to apply for the program as it gives you unique bioengineer recently shared some of her thoughts on the experience. insight from the perspective of those reviewing applications. It is not something I would have learned in a classroom, and I am sure no The whole experience at the FDA was incredible. The working matter what path my career takes after graduation, the experience will environment there truly seemed great. I thoroughly enjoyed all of my make me more valuable as an employee and team member. coworkers. They were all very smart and very enjoyable to interact with. And it was so wonderful getting a whole ten weeks to experience Washington D.C. I also ventured up to Boston one weekend and New York City two weekends, so I really got a fulfilling experience. In my internship I was assigned to the ophthalmic section of CDRH. Veronica Bradley is studying Bioengineering I loved getting to learn so much about medical devices, both from at UCSD. reading documentation of the review process and from discussions with the people in my division. I particularly enjoyed reading about the mechanical testing performed, due to my engineering major. I was able to see how so much of what I’ve learned is applied in the testing of devices. It gave me a new perspective on how essential these concepts are in getting a device to market. I had a specific project I was responsible for (as well as other side projects), and it was so interesting to me. It was a challenge, but I was able to complete it and feel that I accomplished something over the ten weeks. Under the supervision of an experienced reviewer, I worked with a fellow intern in gathering historical information regarding the pre-clinical testing requirements that have historically been requested for the clearance of Lacrimal System Repair devices. After reading through extensive documentation of reviews for all the lacrimal repair devices, including stents and balloons, that have been brought to market over the past thirty years, I was able to create a recommendation for the crucial testing and standards to be written into the new regulation and special controls for this device type. Writing a new regulation and guidance is a complicated process that takes time, but the research I did and the spreadsheet of information I compiled will serve as an essential starting point in the process. It felt good to
10 Biocom LifeLines Fall 2015 TM ProSci Custom Monoclonal Abs Against Challenging Antigens
ProSci’s Hybridoma Development + =
Phase I: • 5 BALB/c mice Phase II: • 1 mouse spleen Phase III: • 2 subcloning steps Immunization • ELISA screening Fusion • ELISA screening Subcloning • ELISA screening • ≥ 6 weeks • 2 weeks • 4-6 weeks
Special mAb Development Call and use BIOCOM153 NEW Cell Surface Proteins code for 25% off! Custom Idiotype First time customers. VHH Antibody Monoclonal Antibody Pairs Development Post Translational Modifications • In vitro & ascites services available Single Amino Acid Mutations • >95% hybridoma fusion success rate Small Molecules • 3 ELISA positive final clones guaranteed • Flexible entry and exit points for services
Custom Your Antibody Experts
• >12,000 custom antibody projects completed since 1998 ProSci is an antibody focused company and a leading • In-house labs & 150,000 ft2 of animal facilities on 27 acres provider of custom antibody services and catalog • USDA licensed & NIH/OLAW assured facilities antibodies worldwide.
prosci-inc.com | [email protected] | (858) 513 2638 © 2015 ProSci Incorporated. All rights reserved. EVENTS By Ashleigh Berry, Manager of Events
Biocom Launches New Speaker Series
Ever wonder how Biocom events are organized and executed? planning every year, and it finishes in January,” said Flatley. “So at Do you have ideas for new topics or dynamic speakers? Would it the time they became hostile, we had a perfectly fresh three-year be interesting to help plan the 60-plus events and conferences strategic plan that allowed us to create a very strong case to our Biocom offers each year? shareholders.” Well, you can. Biocom is always exploring innovative ways to Flatley explained that neither their board nor their shareholders build our member event roster. We are ever waivered. Illumina is now trading consistently evaluating our events to around $200 a share. ensure these programs are meeting our Flatley went on to discuss genome members’ needs. The feedback we receive sequencing. He explained that the more from attendees is extremely helpful; genomes we sequence, the more accurate however, it’s the support from our event the data will become, ultimately providing planning committees that really guide us. a greater ability to drive preventive care. Our committees help us determine how to Flatley was one of the first to have his structure programs, develop content and genome sequenced, discovering he has identify which events are essential for our malignant hypothermia, which can cause members. sudden death under anesthesia. He can Earlier this year, in partnership with our now prevent this from happening. CFO committee, Biocom launched a new Flatley’s story is just one example of how speaker series geared towards CEOs and high-level executives. This genome sequencing can change lives. Illumina has successfully new series will be held twice a year and will highlight a CEO from a lowered the cost for full genome sequencing to roughly $1,000, billion-dollar life science company, providing a unique opportunity and the current cost for individual sequencing is around $2,900. to hear how these companies became successful and maintained Flatley hopes that, in the future, this will be paid by insurance. their value in the ever-changing capital markets. Flatley ended his dynamic discussion by stating, “I’m sort of a With a market cap over $30 billion, it seemed appropriate to kick start-up guy, at least I used to be, and now I am managing this big off the first series with one of our region’s luminaries: Jay Flatley, company. I’m sort of learning as I go.” CEO at Illumina. Flatley sat alongside Joe Panetta, Biocom’s A highlights video of the event is now available on Biocom’s president and CEO, to discuss the genomic revolution and how it YouTube channel. To watch this video, and view a list of Biocom’s will advance health and wellbeing. Flatley was appointed president upcoming events, please visit www.biocom.org. and CEO of Illumina in 1999 and has increased revenue from $1.3 If you are interested in participating in one of Biocom’s event million in 2000 to more than $1.8 billion in 2014. He oversaw planning committees for 2016, opportunitites are available with the company’s expansion into whole genome sequencing, with DeviceFest, the California Life Science HR Conference, Outsourced the Solexa acquisition in 2006, and more recently into clinical Pharma West Conference and BIO 2016. markets, such as oncology and reproductive health. In July 2015, more than 200 attendees heard Flatley discuss his thoughts on Illumina’s past, present and future. He shared his views on competition with start-up companies, genome sequencing Ashleigh Berry is the Manager of Events for Biocom and is in charge of organizing and and much more. marketing Biocom Events. Not surprisingly, attendees were eager to hear Flatley discuss Roche’s hostile takeover attempt. After a collapse in stock price dropped Illumina to $24 per share in December 2011, Roche decided to acquire the company. Roche knew Illumina had unbeatable sequencing technology and, with the stock price so low, would be an easy takeover target. They were mistaken. “One really important factor was that we do a rigorous strategic
12 Biocom LifeLines Fall 2015 MEMBERSHIP By Michelle Wright, Manager of Membership
Member Services: Responding to Your Needs
Biocom is always listening, and we pride ourselves on keeping telemedicine to genomic testing. These technologies allow the lines of communication open. This means meeting with our patients to communicate directly with their physicians, transmit members, listening carefully to their needs and understanding each health care information instantly in a home setting, and company’s challenges and goals. These ongoing conversations help empower them to be active participants in their everyday care us allocate our resources to ensure we provide the best possible management. Studies also show that they help reduce costs and services. improve patient outcomes across a wide spectrum of disease One way we’ve responded to these conversations is to increase conditions. Our mission is to support digital health innovation our efforts to support employees and help them get involved with in our region thus making Southern California the epicenter of their life science community. Each year, Biocom offers more wireless health. than 75 events to help staff grow their personal and professional networks. In the same vein, we also have 15 committees, such as Big Data CRO, legislative and medical devices to join, we host professional Biocom’s Big Data/Informatics initiative recognizes that development courses, offer speaking opportunities on a wide companies everywhere are trying to manage a big data tsunami. variety of panels, offer volunteering opportunities at the San From molecular diagnostics to patient data, our members are Diego Festival of Science & Engineering Expo Day and produce faced with the unique challenge of separating nuggets of the Biocommunique eNewsletter to keep members abreast of the important, actionable data from gigabytes of statistical noise. latest life science news. In addition, our Employee Perks program This initiative helps identify the new trends and best practices helps members save money at local businesses. in data generation, knowledge management and information Naturally, we also offer many opportunities for companies to technology. sponsor events, as well as connecting member companies to keep contracts and collaborations in the family. More than 93 percent If you would like to discuss ways to get more plugged into of companies who use the Biocom Purchasing Group recoup their your membership or review your benefits, please contact me at membership investment each year – many save 15 to 25 times 858.455.0300 x116 or [email protected]. their annual dues. Given these perks, it’s no surprise that Biocom has such high retention. Most recent, one of the top requests members have is to forge closer relationships with clinical sites. To help support this request, we host a variety of events that focus on specific therapeutic areas. Michelle is the Manager of Membership for Biocom and oversees the Medical Device Many more of these events are coming in 2016. Committee for the organization We also help companies get valuable face-time with key dealmakers during Venture Days, Partner Days and Biocom’s Global Life Science Partnering Conference.
NEW INITIATIVES There are a number of major life science issues, but two of the biggest are digital health and big data. To stay on the leading edge of these and other trends, Biocom continues to develop new initiatives to educate stakeholders and show off some of our member’s most important advances.
Digital Health Health care is at the cusp of a sector-wide transformation due in large part to the development of digital health technologies, from mobile applications to remote patient monitoring to
Biocom LifeLines Fall 2015 13 BENEFITS
Evaluating our Health Insurance Trust
The Beyond Benefits Trust, a health benefits program exclusively increases heading into 2016. The industry average is in the for Biocom members, gives California life science companies high teens. This gap will continue to increase, pulling the trust’s access to best-in-class group health insurance. The trust was premiums further away from industry norms and making it the created after a two-year competitive bidding process, which was clear choice for companies with more than four employees. organized by the Biocom Purchasing Because of the trust’s performance, Group and BayBio in 2012. Anthem has also agreed to quote a Come January 1, 2016 employers Beyond Benefits won out over of a with 51-100 employees will be categorized as 5 to 7 percent discount on larger number of group health insurance “SMALL GROUP EMPLOYERS” groups that may have credibility on candidates, including PEO’s, self- their own or may be considering self- insured models, other MEWA trusts The insuring. I’m sure you can imagine What does and several stand-alone discount NOT this mean? what 5 to 7 percent off a large group insurance programs. so good stuff... health premium could mean to a
The Beyond Benefits Trust, like Medical rates will now be based on each The company’s bottom line. We have covered family members’ age and zip code of all of our contracts, was selected the employer. ... worked extensively with Anthem to Depending on your company’s size, medical Alternative by a committee of experts, from our rates could increase 30-40%. provide this benefit and appreciate Enroll in a Department of Labor-qualified member base and board of directors, small business trust, like... their investment in our industry and Impact on Employers who bring decades of industry our member base. Lose Gain knowledge and expertise. We are Underwriting discounts Rising medical We cannot underscore enough how for industry and premiums demographics very fortunate to have a strong Keep your large group qualification, regardless important it is that these discounted Online benefit More administrative of size and connection to these experts, and administration burden avoid... rates are substantiated by actual we do not hesitate to lean on them. Age & zip code claims data from within our trust. based medical rates Additionally, our eight full-time As of August 2015, there are 160 Members Without this claims performance, in the Beyond Benefits Trust. employees use member feedback to Rising medical premiums in the any discounted rates or renewals are industry of 18% vs. Anthem’s prepare competitive bids that test In an e ort to attract larger companies who 8-10% artificial and therefore subject to typically place out of the Trust with their own experience rating, Anthem has conceded to the market, generate more favorable More administrative burden correction in a subsequent year. an aggressive 5-7% rate reduction... terms, provide member remediation WHICH IS A VERY BIG DEAL. Additionally, beginning January services, ensure supplier compliance 1, 2016, employers with 51 to Beyond Benefits—a health benefits program exclusive to Biocom and create value for our members. members—gives California Life Science companies of all sizes access to a 100 benefits-eligible employees group health insurance plan designed to provide best-in-class benefits. Since launching in 2012, Beyond Benefits has saved Life Science companies over Our board of directors and HR $5M in annual medical premium. Learn how you can become a member who are not in the Beyond Benefits advisory groups have recently company and start saving: beyond-benefits.org Trust will be reclassified as ‘small reviewed the Beyond Benefits group employers’. This will have a Trust, evaluated the alternatives in the marketplace and are tremendous impact and could potentially increase their rates by quite confident these benefits, provided by Anthem, are the best 30 to 40 percent, depending on size. available in California. The additional free services and value- This change is tied to rules that apply to small groups, which are added resources under this trust, coupled with unmatched pricing, charged age-based rates. In other words, cost is assessed based make it the preeminent health insurance choice for any industry on the age of each employee and spouse in the group. This shift company. impacts many employers, especially life science companies that In just over two years, the trust has welcomed 160 companies, typically employ between 51 and 100, and adds another obstacle with a 99 percent retention rate, saving them $5 million in annual to offering affordable health care. medical premiums. More importantly, the trust now covers enough Our board, member advisory committees and hundreds of actively people and is large enough to withstand claim fluctuations. This participating member companies could not be more bullish on the credibility allows the trust to offer substantiated renewal rates well value of the Beyond Benefits Trust. We are confident you will see below market standards. that value continue to improve in the coming years. The Beyond Benefits Trust will again see single-digit price
14 Biocom LifeLines Fall 2015 Let’s talk.
See how new advances in 1,536-well qPCR are enabling more biologically relevant high-throughput screening data using fully automated workfl ows and multiple applications with the LightCycler® 1536 System.
For access to presentations, data and a white paper, visit go.roche.com/LC1536 or text HTS to 313131
For life science research only. Not for use in diagnostic procedures. Roche Diagnostics Corporation LIGHTCYCLER is a trademark of Roche. The LightCycler® 1536 Multiwell Plate is manufactured under license from IT-IS International Ltd. 9115 Hague Road © 2015 Roche 581-60993-0515 Indianapolis, Indiana 46256
LC1536_shuffle_BiocomLifelines.indd 1 9/23/2015 10:25:21 AM COMPLEX PROBLEMS REQUIRE SOPHISTICATED SOLUTIONS. For over 160 years, VWR has been growing strong because of our unique approach to collaborating and encouraging innovation with our customers. Over time they have been challenged with finding the answers that help improve lives. Our mission is to enable this by eliminating the process complexities and identifying product and service solutions that help labs and production facilities work better, faster, and smarter. Through our global reach and knowledgeable associates, we proudly excel in delivering solutions that improve productivity, accelerate discovery, and encourage innovation.
PRODUCT CHOICE. SIMPLIFIED. VWR enables science by providing our customers the broadest range of choice in quality products, delivered by a team of people focused on your success. • Over 2 million products - offering unparalleled choice with best in class brands. • VWR collection of brands - from everyday products to specialized solutions. • Custom chemical blends - from our VWR Custom Manufacturing Services. Together, VWR and Biocom combine our core strengths to offer total solutions that advance scientific innovation in the life sciences, providing you with substantial cost savings and service solutions to accelerate science from discovery to production. Extend your purchasing power by taking advantage of the power of the VWR-Biocom partnership, and realize a total solution platform, so you can focus on what's truly important: Science. BIOCOM INSTITUTE By Liisa Bozinovic, Executive Director, Biocom Institute Never Stop Learning
Talent…people… workforce…staff…employees: these are our now a full-time research associate for Silicon and has had an industry’s most important asset. But in the fast-moving biomedical opportunity to lead her own project, expanding her scientific ecosystem, continuing education is key to retaining that value. knowledge. Our program gave her “the tools to learn how to network At Biocom, we have provided educational and professional and gain meaningful employment.” development opportunities since the beginning. As we celebrate The EDGE program has provided internships for one hundred our 20-year anniversary, we thought it would be fun to take a look participants and training opportunities in biofuels and industrial at where graduates from some of our programs are now. biotechnology for hundreds more. Tim Phillips got a job with Lab to Leader graduate, Niko Gubernator started as a scientist Verdezyne less than ten days after finishing the program and has without a business background. He had questions about how to been promoted from process development technician I to process lead people. His company, eMolecules, went from three employees development technician II. in 2008 to forty today. Now the company’s CEO, Gubernator Julie Kim credits the EDGE Program with jump-starting her attributes his success as a leader to the team at the Leadership professional development. Julie completed an internship at Edge. Niko reflected, “it is unfortunate how little training scientists Sapphire Energy in 2011. get.” Fortunately, this program helped him quickly learn to better “The internship itself was the most valuable aspect of the course, relate to his employees by being more transparent. as it provided hands-on skills in the fast-paced biotech industry Erick Espinoza, an immigrant from Mexico who was a sophomore setting. My internship provided me with the experience I needed in high school, arrived in the United States seven months before to land a job as a full-time associate scientist at a pharmaceutical entering the Life Sciences Summer Immersion Program (LSSI) in company, where I continue to work after 4 years.” Julie currently 2012. In Mexico, he had taken high school biology and chemistry works at J&J. courses, but for the first seven months in the United States, he At the Institute, we are passionate about providing access to focused on improving his English. LSSI gave Erick the opportunity quality programs to support both the current and future workforce. to work on a project at The Scripps Research Institute, which led to From CEOs to scientists to budding engineers, one thing we all a 3D image of the multi-protein complex SWR1. Understanding the have in common is that we should never stop learning. active sites and functions of that protein has further implications for the medical field. The program helped Erick step out of his comfort zone. “I learned things I never thought I would before, and I not only mastered them Liisa Bozinovic is the Executive Director of but, gave a presentation to other scientists, parents and teachers,” the Biocom Institute and also heads Biocom’s said Erick. Today, he is a junior at UC Riverside, studying pre-med HR Initiative. and doing research in astrophysics. More than one of his college essays incorporated his LSSI experience. Many veterans have said that transitioning to civilian life is more difficult than anything they ever did in the military. Amanda Gerber completed her bachelors in science after her military service. She even did some work in a lab while going to school. When she graduated, her goal was to work in a research lab and, living in San Diego, a lab in a biotech company was appealing to her. Gerber did not have enough experience for an entry-level research job until she entered the Biocom Institute’s Veteran Career Mentoring Program earlier this year. She was paired with Rich Pascoe, CEO of Apricus Biosciences and also a veteran, and accepted a program-funded internship with Silicon Biosciences. The funded internship gave Silicon an opportunity to try out Professional Development Amanda as an employee without any financial risks. Amanda is
Biocom LifeLines Fall 2015 17 SCIENCE FESTIVAL By Sara Pagano, Managing Director, SD Festival of Science & Engineering STEM is the New Trend
You have heard the expression that pink is the new black, well more than those with master’s degrees in non-STEM occupations. in the world of research and education, STEM is the new trend. In fact, 47 percent of bachelor’s degrees in STEM occupations STEM (science, technology, engineering and math) is accelerating earn more than PhDs in non-STEM occupations. faster than we can keep up: STEM in sports, afterschool STEM, “Qualcomm believes that increasing the number of STEM STEM pathways, cooking lessons integrating STEM concepts. The graduates, as well as the level of diversity in the talent pipeline, is U.S. Department of Education is stressing STEM’s importance to the challenge that the entire industry needs to focus on solving,” maintain our global leadership. says Charles Bergan, vice president of engineering, Qualcomm “In a world that’s becoming Technologies, Inc. “Encouraging increasingly complex, where students from elementary to high success is driven not only by what school to pursue their interests you know, but by what you can in science and engineering is do with what you know, it’s more one of the best ways to ensure important than ever for our youth that our technology companies to be equipped with the knowledge can continue to innovate in an and skills to solve tough problems, increasingly competitive world gather and evaluate evidence market.” and make sense of information,” We all know that San Diego says the DOE’s STEM web page. offers a strong foundation for “These are the types of skills new company creation and that students learn by studying development. The city continues science, technology, engineering to be a catalyst for emerging and math—subjects collectively young innovators, showcasing that known as STEM.” we can have it all in San Diego: go Why is STEM so big? Because to school, conduct research, find of what it means for our future internships and get an amazing workforce. How do we keep it job here to complete the circle going for future generations? of homegrown workforce that We start young and look at how continues to make an economic technology is becoming the foundation for STEM learning. impact. Living in an age of science and technology, STEM affects “It appears that STEM-focused learning will continue to be a our daily lives and will continue to be the driving force behind top priority in education because of the growing need for a STEM- future growth. It is crucial that children are inspired, motivated ready workforce,” says Tory See, community relations director at and educated in STEM. ViaSat. “Beyond the usual STEM careers, we will see technology Do you want to inspire the next generation of innovator? Save the integrated into many developing jobs, even those that ordinarily date for the 2016 San Diego Festival of Science & Engineering. wouldn’t be considered a STEM career. With the rapid pace of jobs EXPO Day kicks off on Saturday, March 5, followed by a stellar that are developing to support our changing world, we need to be week of programming throughout San Diego (March 6-13, 2016). ready to teach students in a way that will allow them to adapt to For more information or to learn more about sponsorship and these changes. Because of this, it is imperative that industry be exhibitor opportunities, visit www.lovestemsd.org. supportive of STEM initiatives and education. This support helps teachers to better understand where industry is currently at and Sara Pagano is the Managing Director of the headed, and enables them to prepare students who STEM career San Diego Festival of Science & Engineering ready and builds the pipeline of the next generation of workforce.” The need for students with STEM-related core concentrations **Graphic: U.S. Department of Education is rapidly growing. These jobs are making an economic impact in San Diego and around the world. A report from the Georgetown University Center on Education and the Workforce found that 65 percent of people with bachelor’s degrees in STEM fields earn
18 Biocom LifeLines Fall 2015
MEMBERS IN ACTION
WE’VE BEEN BUSY: Biocom continues to provide a wide variety of opportunities for members to come together and for the Southern California region to highlight its many attributes. Featured here are a collage of photos from the September breakfast meeting, the Fire Side chat with Jay Flatley, Illumina, the Facilities 102 workshop, the BIO International Convention, BIO Japan, the AdvaMed 2015 MedTech Conference, and the Biocom Water Workshop.
Photo by J.T. MacMillan Photography Photo by J.T. MacMillan Photography
20 Biocom LifeLines Fall 2015 MEMBERS IN ACTION
PAC LEGISLATIVE STAFF RECEPTION & BIOCOM PAC LEGISLATORS RECEPTION : The Biocom PAC (Political Action Committee) is a non-partisan California state committee established to fundraise and make political contributions to elect candidates and promote issues that will improve the environment for business and innovation for the life science industry in Southern California. Biocom PAC contributors (individuals and corporations) enjoy a variety of benefits including admission to many Southern California political events. The Biocom PAC conducts two annual signature events, the Biocom PAC Elected Officials Reception and its Legislative Staff Appreciation Reception, which is the only event of its kind in the area.
Atheln is a Contract Development Organization delivering solutions to biopharma companies
Innovative virtual product development approach Multidisciplinary strategy and plans from early stage to exit Team of industry seasoned experts excel in delivering solutions for risk control Integration of technical and commercial considerations to maximize product value
www.athelnbiomed.com [email protected] / [email protected] 310.220.4332 858.554.0636
Atheln-BioCom-Ad-May2015-revision3.indd 1 5/15/15 10:13 AM MEMBERS IN ACTION
BIOCOM OPEN HOUSE: This year marks the 20th anniversary for Biocom, so we decided to throw a housewarming party in our new home. Attendees gathered to our new space on Thursday, October 1st for our Annual Open House and Purchasing Group Supplier Showcase, as we did an homage to #throwbackthursday and threw it way back to celebrate 20 years of success in the life science community. Attendees networked and mingled amidst 400+ of their life science colleagues, while perusing the vetted Platinum Suppliers of the Biocom Purchasing Group to learn about the valuable savings and benefits exclusively available to Biocom members.
22 Biocom LifeLines Fall 2015 Congrats BIOCOM on #RadyMade 20 Years of Valuable Service Scientist Entrepreneur
“As a scientist turned entrepreneur, my Rady MBA provided me the business acumen and opportunities to catapult my entrepreneurial journey. Today, I have built a female-focused business accelerator and angel network/fund that has helped launch 56 startups, facilitated 82 women-owned small businesses to think big and created over 50 new jobs.”
Silvia Mah, Ph.D., MBA ‘10 CEO, Hera Labs & Founding Partner, Hera Fund I am RadyMade
NEVER STOP STARTING UP
To see more stories: rady.ucsd.edu/radymade
MBA | MFIN | MSBA | Ph.D. | ExecEd SAVE THE DATE: Biotech Demystified - September 12-14, 2016 Reveal Greater Coverage Depth in WES
Achieve greater coverage depth from less sequencing through the Roche MedExome Supplier A's Clinical Research Exome 60.0 enhanced coverage of the new SeqCap EZ MedExome Target 50.0 Enrichment Kit for whole exome sequencing (WES). Rely on a design 40.0 developed to enrich the entire exome, but particularly optimized for 30.0 analyzing genes of medical relevance (Figure 1) in research studies. 20.0
10.0 • Focus on genomic regions that really matter 0.0 For disease-associated genes, 98% of bases are covered at ≥20X depth. <90% 90-97% 97-100% 100% Percent of total GeneTests genes covered Percent of total GeneTests Percent of each GeneTests gene’s coding bases covered at ≥20X • Call variants with confidence
Figure 1. With SeqCap EZ MedExome, 53% of Detect SNPs with 98% sensitivity and >99% specificity for SNP allele medically relevant genes are covered at 100% classification. (≥20X coverage) vs. 6% by Supplier A’s Clinical Research Exome. Percentage of bases covered at • Gain greater efficiency at minimal cost ≥20X for each consolidated target was determined using GATK (DepthOfCoverage), summarized by gene. Reduce sequencing cost through uniform coverage and fully supported Supplier A kit’s data was generated by a third-party multiplexing protocols. sequencing service provider, following Supplier A’s protocol. All reads were subsampled to 60 million for Reveal more about the exome assessment, then subjected to the same bioinformatics pipeline for analysis. Roche data on fi le. Learn more about how the SeqCap EZ MedExome Target Enrichment Kit can improve your whole exome sequencing by visiting sequencing.roche.com/medexome.html or calling 800-262-4911.
For life science research only. Not for use in diagnostic procedures. Roche Diagnostics Corporation NIMBLEGEN and SEQCAP are trademarks of Roche. 9115 Hague Road © 2015 Roche 581-61699-0915 Indianapolis, Indiana 46256
SeqCapMedExome_AJHG.indd 1 9/23/2015 8:55:01 AM PURCHASING GROUP By Rick Fultz, Managing Director, Biocom Purchasing Group Member Driven Evolution
As Biocom celebrates our 20th year as Southern California’s (RFP) process has dramatically strengthened over the last few premier, member-driven life science industry association, we at years. Our member-driven RFPs are our backbone and serve as an the Biocom Purchasing Group can’t help but reflect on how far ongoing clearinghouse for life science industry trends. we’ve come since our very modest beginnings. In recent years, we have leveraged this world-class combination What began as a small group of life science companies coming of human capital, knowledge and combined spending to secure together to negotiate terms for basic lab supplies has grown into a first-of-its-kind life science healthcare trust, an international a vehicle with global reach that now generates $120 million in travel program, nationally-competitive office product and furniture member savings each year. contracts and a one-of-a-kind garment and cleanroom contract. In With offerings that include lab supplies, office supplies, specialty 2016, we will deliver an industry-changing lab supply contract, gases, shipping, travel and health insurance, companies can find industrial gas contract, global shipping agreement and several many ways to take advantage of the program. Most are saving 15 other new contract areas. to 25 times their annual membership dues. Increasing the depth of our due diligence has been key to our By leveraging hundreds of millions of dollars in collective evolution as the most valued group purchasing organization in the spending and providing Biocom Purchasing Group suppliers with world. We strive to better serve our membership and create the opportunities to enhance their organizations, we can negotiate robust portfolio of savings that will lead to success for our member price points that consistently beat national group purchasing companies. To be a part of this exciting evolution in 2016, please organizations (GPOs) like Premier, Novation, Med Assets, Core contact any one of our Biocom Purchasing Group staff for more Trust and others. information. In addition to discounts and services, industry companies can leverage our systems and staff to assist them (free of charge) with contract compliance, due diligence, quality assurance and market assessment. Our compliance team tracks all Purchasing Rick Fultz oversees membership and Group contracts and closely monitors our formal Member sponsorship efforts, business development Feedback Program. They meet regularly with members and opportunities, and the Biocom Purchasing operate as a neutral, third-party advisor, translating feedback into Group. solutions and building trust every step of the way. Additionally, member companies can find assistance with conflict mediation, procurement and supply chain best practices, as well as gain access to industry educational seminars and enhanced member collaboration. Our members are engaged at every level: from the committees that select and oversee our contracts to the board that steers the direction of the organization. It is this comprehensive participation that has made the Biocom Purchasing Group a trusted advisor and industry leader in life science operational success. This evolution of the Biocom Purchasing Group also comes with great responsibility. We are representing one of the most powerful and influential life science industries in the nation, and we owe it to our members to negotiate outstanding contracts with leading service providers. Biocom members are no longer satisfied with mediocre price concessions, nor will they stand for anything short of best-in- class customer service and dedicated, Biocom member- only resources. As a result of this clout, our high-caliber request for proposal
Biocom LifeLines Fall 2015 25 PREMIUM MEMBER SPOTLIGHTS
PREMIUM MEMBERS AbbVie Cooley LLP Mentus Airgas Deloitte Merck Research Laboratories of San Diego Aldevron DLA Piper Mintz, Levin, Cohn, Ferris, Glovsky and Alexandria Real Estate Equities Dowling & Yahnke* Popeo Althea Eli Lilly NuVasive Arena Pharmaceuticals Ernst & Young Office Depot Bayer Healthcare Evaluate Pharma Pfizer Biogen Ferring Research Institute Prometheus Laboratories Biomed Realty Trust Fisher Scientific PwC Biospace GE Healthcare Life Sciences Thermo Fisher Scientific Bridge Bank* Genoptix Unisource Solutions California Manufacturing Technology Hologic VWR International Consulting J-Labs Wilson Sonsini Goodrich & Rosati Canale Communications Jones Day Celgene KPBS City National Bank KPMG COI Pharmaceuticals Latham & Watkins Conatus Pharmaceuticals Mallinckrodt Plc * New Members from May 2015 to October 2015
www.biomedrealty.com
Name: Tracy Murphy Job title: Regional Vice President, San Diego Favorite website: OfficeSnapShots Favorite spot in Southern California: Pony Room @ Rancho Valencia First job: Pre-College – Art Gallery, Post-College -Marketing Director BRE Commercial Favorite movie: Old School (recently acquired by Cushman Wakefield) Favorite books: Winning by Jack Welch Favorite part of your job: Strategy of Repositioning Assets Favorite quote: “Individual commitment to a group effort – that If you could have another career, what would it be: Interior Designer is what makes a team work, a company work, a society work, a Why did you start working in your industry: Through real estate specific to the life science civilization work.” – Vince Lombardi industry, I felt like I could support the brightest minds pursuing change in the most Favorite TV show: CBS Sunday Morning important causes. Favorite restaurant or meal: Qero, Encinitas Favorite city: US: Chicago EU: Amsterdam Favorite actor/actress: Matt Damon/Christina Applegate Favorite thing to do on the weekends: any sport with my boys What CD can we find in your car: Kygo Favorite hobby: Painting
26 Biocom LifeLines Fall 2015 Abzena expands into Southern California
The Abzena group has undergone a signifi cant transformati on in the past few years following the acquisiti on of Anti tope in 2013 and Pacifi cGMP in 2015. Bringing together these companies allows Abzena to support customer’s projects seamlessly from lead selecti on through to GMP manufacturing for clinical trials.
Now enabling bett er biopharmaceuti cals from more locati ons.
GMP manufacturing that specializes in single-use technology for the producti on of biopharmaceuti cals for Phase I and Phase II clinical trials Process development focuses on improving yield at each stage of development by opti mizing each step in the process
San Diego, USA San Diego, Coventry, UK R&D site for developing and synthesising conjugati on and PEGylati on reagents
PolyPEG™ a low viscosity polymer to make it easier to manufacture and inject long-acti ng therapeuti c proteins
Cambridge, UK
iTope and TCED™ to identi fy T cell epitopes Biosimilar cell line development in CHO, using a proprietary database and algorithm NS0 and SP2/0 including enhanced PQA
EpiScreen™ for ex vivo assessment of the ThioBridge™ for the generati on of more immunogenicity of biopharmaceuti cals homogeneous anti body drug conjugates
Composite Human Anti body™ technology TheraPEG™, CyPEG™ and HiPEG™ for to humanise and deimmunise anti bodies linking polymers to therapeuti c proteins to extend their durati on of acti on Composite Protein™ technology for deimmunisati on of therapeuti c proteins
Composite CHO™ to produce high expressing cell lines for manufacture
Start your project today. Visit www.abzena.com PREMIUM MEMBER SPOTLIGHTS
www.bridgebank.com
Your Name: Rob Lake Favorite spot in Southern California: Del Mar Beach Job title: SVP, Head of Life Sciences First job: Weekend shift at White Castle Favorite part of your job: Coming up with creative solutions to help people solve complicated Favorite movie: TRemember the Titans problems. Favorite book: Tuxedo Park by Jennet Conant If you could have another career, what would it be: Medical Doctor Favorite quote: “I learned that courage was not the absence of fear, Why did you start working in your industry: It was intriguing to be able to apply my skills in but the triumph over it. The brave man is not he who does not feel commercial finance to the life sciences sector. For me personally, doing what I do is not only afraid, but he who conquers that fear.” – Nelson Mandela a job and a career, it’s philanthropic. It feels good to be able to help life sciences companies Favorite TV show: Seinfeld with their financial needs in a concerted effort to save and improve peoples’ lives. Favorite restaurant or meal: Gramercy Tavern in NYC Favorite city: Chicago, IL (during the summer) and San Diego, CA (all other times) Favorite actor/actress: Robert De Niro / Gwyneth Paltrow Favorite thing to do on the weekends: Spend time with family (my wife, 4-year old boy, and 6-month old girl) & friends What CD can we find in your car: Hullabaloo (I lost control of the music selection a couple of years ago.) Favorite hobby: Home improvement Favorite website: Amazon.com
new discoveries start HERE ASCB 2015 is your direct line to the most innovative and exciting research being done in basic cell biology today. Our researchers—the top minds in life sciences—are moving the needle in biophysics, neuroscience, cancer biology, immunology, synthetic biology, and bioinformatics. Use this extraordinary opportunity to connect with those on the cutting edge of applied discovery. The best patents come from the best basic research. The best basic research will be presented at ASCB 2015.
We want to see you at our meeting, so we’re being flexible! New this year, ASCB is offering one-day registration, to better accommodate your schedule. It’s more convenient and inexpensive than ever to participate in our meeting! EXHIBIT BOOTHS STILL AVAILABLE ascb.org/2015meeting @ascbiology /ascbiology ascb #ascb15 PREMIUM MEMBER SPOTLIGHTS
www.dywealth.com www.vwr.com
Name: Brett Pernicano Name: Charles McWilliams Job title: Portfolio Manager Job title: Vice President, Strategic Alliances Favorite movie: The Boondock Saints Favorite movie: It’s hard to pick one. When I very young I would Favorite books: The Great Gatsby by F. Scott Fitzgerald have said “Star Wars” Favorite quote: “It takes 20 years to build a reputation and only Favorite books: TI don’t think that I have one, but I enjoyed five minutes to ruin it” – Warren Buffett almost all of Michael Chrichton’s books Favorite TV show: Not big on shows but love ESPN “30 for 30” Favorite quote: Persistence from Calvin Coolidge “Nothing in this Favorite restaurant or meal: I have to stick with my family roots world can take the place of persistence. Talent will not; nothing on this one. Pernicanos Pizza. is more common than unsuccessful men with talent. Genius Favorite city: Born and raised in America’s Finest City San Diego will not; unrewarded genius is almost a proverb. Education will not; the world is full of Favorite actor/actress: Jack Nicholson educated derelicts. Persistence and determination alone are omnipotent. The slogan Press Favorite thing to do on the weekends: Assuming I have the time, I love to play beach On! has solved and always will solve the problems of the human race.” volleyball Favorite TV show: I really don’t watch TV, but I recently watched, and really loved Band of What CD can we find in your car: Who owns CD’s (compact discs) anymore? Brothers Favorite hobby: Golf would definitely be at the top of the list Favorite restaurant or meal: Wahoo’s Fish Tacos Favorite website: The Wall Street Journal (www.wsj.com) Favorite city: Rome Favorite spot in Southern California: Any beach from San Diego north to Santa Barbara Favorite actor/actress: John Wayne First job: I had the distinguished pleasure of working as a driving range assistant at The Favorite thing to do on the weekends: A day at the beach with family and friends Meadows Del Mar Golf Course (aka The Grand Del Mar) What CD can we find in your car: I don’t have CD’s but have a wide music taste that ranges Favorite part of your job: The ah-ha moment in a client meeting where the portrait I paint from current top hits to hip hop. Anything but country. for my clients is actually seen. Favorite hobby: Do people listed to CDs any more? I listen to Pandora, and it’s based on If you could have another career, what would it be: A surgeon. Since I was a kid I have always my mood wanted to get into the medical field. Favorite website: Netflix Why did you start working in your industry: Once I purchased my first mutual fund at the age Favorite spot in Southern California: Abalone cove of 16 I knew I was hooked. When I found a profession I could help people while working First job: Courtesy Clerk in Grocery Store with investments it was a perfect match. Favorite part of your job: Working with great people If you could have another career, what would it be: I had always wanted to be an Astronaut. It seems far fetched, but if I could could do one thing that would still be it. Why did you start working in your industry: I set out intending to work in a tech company, but I found something much better in the LifeSciences! BIOCOM SPOTLIGHT
Name: Melanie Nally Favorite thing to do on the weekends: Explore new restaurants and breweries Job title: Associate Director of Local Government What CD can we find in your car: Ray LaMontagne & Regulatory Affairs Favorite hobby: Traveling Favorite website: www.manrepeller.com Favorite movie: Amelie Favorite spot in Southern California: North Park Favorite books: The Fountainhead First job: Taco Bell Favorite quote: “Your time is limited, so don’t waste it living Favorite part of your job: Working hands-on with elected officials and regulators to create someone else’s life. Don’t be trapped by dogma – which policies that positively impact our members. is living with the results of other people’s thinking. Don’t If you could have another career, what would it be: Fashion buyer let the noise of other’s opinions drown out your own inner Why did you start working in your industry: I was introduced to Biocom by Jimmy Jackson in 2005 voice. And most important, have the courage to follow your heart and intuition. They somehow and have wanted to work for him ever since (seriously!). I was working for an elected official at already know what you truly want to become. Everything else is secondary.” - Steve Jobs, 2005 the time, and was drawn to the industry because of everything it does to alleviate disease and Stanford Commencement Address advance medical care. Favorite TV show: Sons of Anarchy Favorite restaurant or meal: Urban Solace Favorite city: Paris Favorite actor/actress: Edward Norton/Keira Knightley
Biocom LifeLines Fall 2015 29 BOARD OF DIRECTORS
BOARD OFFICERS AND EXECUTIVE COMMITTEE: Damien McDevitt, Ph.D., GlaxoSmithKline CHAIR: Theodore Schroeder* Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* VICE CHAIR: Carin Canale-Theakston, Canale Communications* William Molloie, PwC CHAIR ELECT: Daniel Burgess* Tracy Murphy, Biomed Realty Trust VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper* Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* Perry Nisen, M.D., Ph.D., Sanford-Burnham Medical Research Institute VICE PRESIDENT – INDUSTRY: Christophe Schilling, Ph.D., Genomatica, Inc.* Brian O’Callaghan VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* Kenneth Polin, Jones Day CHAIR EMERITUS: Magda Marquet, Ph.D., Althea (A member of the Ajinomoto Group)* Trindl Reeves, Barney & Barney LLC* PRESIDENT & CEO: Joe Panetta, Biocom* Gregory Reyes, M.D., Ph.D., Celgene Vincent Anido, Ph.D., Aerie Pharmaceuticals Dan Ryan, Alexandria Real Estate Equities Steven Bartz, Ph.D., Merck & Company Camille Saltman, Malama Composites, Inc. Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo James Schaeffer, Ph.D., Calibr* Michael Boyd, AbbVie Timothy Scott, Pharmatek* Michael Brown, Stradling Yocca Carlson & Rauth Bhasker Shetty, Ph.D., Pfizer La Jolla Terrance J. Bruggeman Larry Stambaugh, Kalos Therapeutics* Carol Cox, NuVasive Mark Stevenson, Thermo Fisher Scientific* John M. Dunn Tsuneo Takahashi, NF Corporation Stephen Ferruolo, J.D., Ph.D., USD School of Law* Scott N. Wolfe, Latham & Watkins Oliver Fetzer, Ph.D., Synthetic Genomics M. Wainwright Fishburn, Jr., Cooley LLP* LIFE DIRECTOR: Don Fitzgerald, Genentech Kennon W. Baldwin, Ferguson Pape Baldwin Architects* Jack Florio David Hale, Hale BioPharma Ventures* Gregory Fond, Sanofi Global R&D Tina Nova, Ph.D., Molecular Stethoscope Gregory Frost Carol Gallagher Biocom Board Members-Ex-Officio: Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Sandra Brown, Ph.D., UCSD Richard Heyman, Ph.D. Mark Cafferty, San Diego Regional Economic Development Corporation Elliot Hirshman, Ph.D., San Diego State University Constance Carroll, Ph.D., San Diego Community College District Matthew Hudes, Deloitte LLP Scott Lippman, MD, Moores Cancer Center, UCSD Guy J. Iannuzzi, Mentus Greg McKee, CONNECT Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation Peter Preuss, The Preuss Foundation David Kabakoff, Ph.D., Sofinnova Ventures Jerry Sanders, San Diego Regional Chamber of Commerce Katherine Kantardjieff, Ph.D., California State University San Marcos David Webb, Ph.D., Scripps Research Institute Paul Laikind, Ph.D., ViaCyte Jacob Levin, Ph.D., UC Irvine *Executive Committee Member James Levine, Sapphire Energy* Jack Lief* John Lister, Dexcom
COMMITTEE LEADERSHIP
BIG DATA FDA Committee Digital Health Committee Larry Smarr, Cal(IT)2 Magda Marquet, Ph.D., Althea (A member of the Apurv Kamath, Dexcom Ajinomoto Group) Biocom Institute Board Committee* Public Policy Oversight Committee* Michele Yelmene Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. Larry Stambaugh, Kalos Therapeutics Intellectual Property and Patent Law Committee Capital Development Committee* Paul Laikind, ViaCyte Daniel Hart, Knobbe Martens Olson & Bear LLP Canale Communications Purchasing Board Committee* Carin Canale-Theakston, Michael Mueller, Conatus Pharmaceuticals Sofinnova Ventures Jack Lief David Kabakoff, Ph.D., International Committee CRO Committee Veterans Committee Kenneth Polin, Jones Day Josh Vosovic Pharmatek Timothy Scott, Legislative Committee Environmental, Health and Safety Committee Richard Ledford *Board Level Committees Cliff Hanna April Grant, Sunovion Pharmaceuticals Dan Shiel, Pfizer La Jolla Medical Device Committee Facilities Committee Mike Oliver, Spectra Science Andy Darragh, Ferguson Pape Baldwin Architects Joleen Schultz, Rady School of Management, UCSD Brent D. Jacobs, Cushman & Wakefield
30 Biocom LifeLines Fall 2015 BIOCOM MEMBERSHIP
Bridge Bank* Dowling & Yahnke* KPBS Pfizer PREMIUM California Manufacturing Eli Lilly KPMG Prometheus Laboratories AbbVie Technology Consulting Ernst & Young Latham & Watkins PwC Airgas Canale Communications Evaluate Pharma Mallinckrodt Plc Thermo Fisher Scientific Aldevron Celgene Ferring Research Institute Mentus Unisource Solutions Alexandria Real Estate Equities City National Bank Fisher Scientific Merck Research Laboratories of VWR International Althea COI Pharmaceuticals GE Healthcare Life Sciences San Diego Wilson Sonsini Goodrich & Arena Pharmaceuticals Conatus Pharmaceuticals Genoptix Mintz, Levin, Cohn, Ferris, Rosati Bayer Healthcare Cooley LLP Hologic Glovsky and Popeo Biogen Deloitte J-Labs NuVasive Biomed Realty Trust DLA Piper Jones Day Office Depot Biospace
3-V Biosciences* CalciMedica Histogen NF Techno Commerce Senté Abcore CannaVest Corporation Human Longevity Nitto Denko Technical Seragon Pharmaceuticals Abgent Cell Applications Huya Bioscience International Novartis Pharmaceuticals SGB Abide Therapeutics Celladon IDEXX BioResearch Novo Nordisk Silicon Biosystems Abilita Bio Cellana Illumina Nucelis Sirenas Marine Discovery Abwiz Bio Center for Aquaculture Technologies Imprimis Pharmaceuticals OBI Pharma USA Solstice Biologics ACADIA Pharmaceuticals Channel Medsystems* Inception Sciences Ocera Therapeutics SomaLogic ActivX Biosciences Chubu Technology Licensing Office Indi Molecular Ohr Pharmaceuticals Sophiris Bio Advanced BioMatrix Cibus Inhibrx Optimum Therapeutics Sorrento Therapeutics Advanced Targeting Systems Cidara Therapeutics InnoPep Orexigen Therapeutics SOVA Pharmaceuticals Aerie Pharmaceuticals Coda Therapeutics Innovative Cell Technologies OrPro Therapeutics Sparsha Pharma USA Agena Bioscience Conju-Probe Innovus Pharmaceuticals Otonomy Stemedica Cell Technologies Aimmune Therapeutics* Contract Biotics Inovio Pharmaceuticals Oxford Bio Therapeutics* StemImmune Ajinomoto Pharmaceuticals Cosmederm Bioscience Integrated DNA Technologies Pacira Pharmaceuticals StemoniX* AM Chemicals Crinetics Pharmaceuticals Intercept Pharmaceuticals Panmira Pharmaceuticals StemProtein* Ambryx Biotechnology Cypher Genomics International Stem Cell Patara Pharma Sunovion Pharmaceuticals Amgen CytomX Therapeutics* Intrexon Corporation Pathway Genomics Synthetic Genomics Amicrobe Dart Neuroscience Intrinsic LifeSciences PersImmune Takeda Pharmaceuticals U.S.A. Amplyx Pharmaceuticals Definiens Invetech Pfenex Tanabe Research Laboratories AnaptysBio Dermata Therapeutics* InvivoGen PharmAkea Tarere Therapeutics* Animal Cell Therapies* Diomics Corporation IRBCo. Polaris Group TEGA Therapeutics Ansun Biopharma DNA Link USA ISIS Pharmaceuticals Polynoma Tenova Pharmaceuticals Apricus Biosciences DNAtrix J-Oil Mills PolyPeptide Group Thesan Pharmaceuticals Aptose Biosciences* DSM Food Specialties JSR Micro Poseida Therapeutics Tocagen Aratome* E&B Technologies Kalos Therapeutics Predictive Biology Tonbo Biosciences Arcturus Therapeutics Edico Genome Kalyra Pharmaceuticals PrimeGen Biotech TP Therapeutics Arcus Bioscience* eFFECTOR Therapeutics Koltan Pharmaceuticals Primordial Genetics Tracon Pharmaceuticals Ardea Biosciences Elcelyx Therapeutics Kura Oncology Prognosys Biosciences Tragara Pharmaceuticals Armetheon* Electronic BioSciences Kyowa Hakko Kirin California ProSci Triphase Accelerator Arrayomics eMolecules La Jolla Biologics QED Bioscience Triton Health & Nutrition Arytha Biosciences Epeius Biotechnologies La Jolla Pharmaceutical Company Quanticel Pharmaceuticals UCB Asahi Kasei Pharma* Epitracker* Ligand Pharmaceuticals Receptos US Specialty Labs Astellas Pharma Equitech Bio Laguna Pharmaceuticals* Regulus Therapeutics Vantari Genetics aTyr Pharma Eton Bioscience Leading Biosciences* REKA Health Vaxiion Therapeutics Auspex Pharmaceuticals Fabrus Lion Biotechnologies* Rempex Pharmaceuticals Verdezyne Avantgen Fate Therapeutics Lpath Renova Therapeutics Vertex Pharmaceuticals Avelas Forge Therapeutics Lumena Pharmaceuticals Ribomed Biotechnologies Vet-Stem Avidity NanoMedicines Genelux Corporation MabVax Therapeutics Ridgeline Engineering ViaCyte Aviva Biosciences Genentech Malama Composites RIFT Biotherapeutics* Vical Bachem Americas Genlantis Mast Therapeutics Roche Applied Science Viking Therapeutics BASF Genoa Pharmaceuticals MDRejuvena Rohto Pharmaceutical Visionary Pharmaceuticals Beloteca* Genomatica MEI Pharma RQX Pharmaceuticals Vital Therapies BioLegend Genovo Corporation Meiji Seika Pharma RuiYi Wellspring Biosciences Biomatrica GenSignia Life Sciences Metacrine* Sapphire Energy Wildcat Discovery Technologies Biomyx GigaGen Mirati Therapeutics Samumed World Fusion US BioNano Genomics GlaxoSmithKline Molecular Stethoscope* Samsara Sciences Xencor Bionomics Global Medical & Research Monsanto Sanofi Yokogawa Electric* Bio Options Technologies MultiVir Scilex Pharmaceuticals* BioSpyder Technologies GWR Instruments Nagano Science USA* Scripps Laboratories BioWa Halozyme Therapeutics Nautilus Environmental Senior Scientific Boehringer-Ingelheim Helix* Neothetics Senju USA Curtana Pharmaceuticals Heron Therapeutics* NeuroGenetic Pharmaceuticals Senomyx * New Members from May 2015 to October 2015
Biocom LifeLines Fall 2015 31 BIOCOM MEMBERSHIP
Bavarian Nordic* DD Studio Mediconomics Robarts Clinical Trials CRO/CMO Behavioral Pharma Drug Delivery Experts MicroConstants Roowin 3DT Holdings Bend Research eStudySite Molecular Response SAFC Pharma Abbiotec BioAtla Evotec* MPI Research Sherpa Clinical Packaging ABL BioBlocks* Exon BioSystems MS Clinical Services* Spaulding Clinical Research Absorption Systems Bioserv Corporation Explora BioLabs My Chem LLC Starfish Medical Accelagen BTS Research Formex Neuroservice SynteractHCR Accugent Laboratories CalChem Synthesis Genea Biocells* Neuro-Sys Therapeutics, Inc. Acurian Cassia Global Blood Therapeutics* Outerspace Design Group Tioga Research Advantar Laboratories Cato Research GRAM Laboratories Pacific Rim Pathology* Toxikon Advin Biotech* Champions Oncology* Hamari Chemical San Diego Research PacificGMP Triligent International Agility Clinical Charles River Laboratories Center PharPoint Research Ultimate Labs Alkahest* ChemDiv HD Biosciences PharmaDirections VIRAPUR Alliance Protein Laboratories ChemPartner* Huntingdon Life Sciences Pharmatek Laboratories Wax-It Histology Services A&M Biomedical Cleave Biosciences* IMS Health PrimaPharm WuXi AppTec American Peptide Company Clintec International* Integrium Clinical Research Profil Institute for Clinical Research Zensun USA AnaBios Combi-Blocks inVentiv Health Clinical PSI CRO Zyagen Animantis Concortis Biosystems IriSys Puracyp Annova Chem Crown Bioscience San Diego iXCells Biotechnologies USA Quadrants Scientific ARIANNE Cytelligen JadeBio Reveal Biosciences Atheln Davos Chemical KaloBios Pharmaceuticals* Rho
Cell Idx FemCap KFx Medical SeaSpine Orthopedics* MEDICAL DEVICE & CeloNova BioSciences Fortimedix USA Lumira* Sequenom Celula Freedom Meditech MARDX Diagnostics Sequent Medical DIAGNOSTIC Cliniqa Corporation GenomeDx Biosciences Medipacs Sienna Labs Acon Laboratories ClinMet GenWay Biotech Micell Technologies Signal Genetics* Aethlon Medical CombiMatrix GIMDx Millennium Health Sirigen Alphatec Spine Compellon Glaukos Corporation Nano Imaging Services Solekai Systems* AltheaDx Critical Diagnostics Glysens Nanomedical Diagnostics Sonendo Amydis Diagnostics CTK Biotech Hitachi Chemical Research Center NuFACE SpectraScience Applied Proteomics CVAC Systems Hygeia Medical Omniome Spinal Elements Astute Medical Cytori Therapeutics Ichor Medical Systems OncoSec Medical Suneva Medical Axonics Modulation Technologies DermTech International Ignyta Organovo Tandem Diabetes Banyan Biomarkers DexCom ImpediMed Parallel 6 Targeson BeneChill Diagnostic Consulting Network ImThera Medical Pediatric Bioscience TherOx Biocept Dorsa Vi USA Inari Medical Prometheus Laboratories Tristan Technologies BioDx Ellipse Technologies Inceptus Medical Qualigen Trovagene Biological Dynamics Emerge Diagnostics INOVA Diagnostics Quidel Uptake Medical Biomerica Endologix Interpreta Quinn Medical Vention Medical* Biospacific* Enigma Diagnostics Interventional Spine ReCor Medical* Yulex bioTheranostics Entra Health InVision Biomedical Group ReShape Medical Bio Trace Medical* Epic Sciences Invivoscribe Technologies REVA Medical Breathe Technologies Epitope Diagnostics Ionian Technologies ReVision Optics Bruin Biometrics Fallbrook Engineering Ivantis Roka Bioscience Burl Concepts*
Human BioMolecular Research Salk Institute For Biological Studies Scripps Health NON-PROFIT Institute San Diego Biomedical Research Scripps Research Institute INDIVIDUAL American Cancer Society, Border Institute of Engineering in Medicine Institute The BioIndustry Association Antoinette Azevedo Sierra Region ISM San Diego San Diego Blood Bank The Lowy Medical Research Institute Bernard King Battelle J. Craig Venter Institute San Diego Clinical and Translational (LMRI) Carol Gallagher Calibr Kaiser Permanente Research Institute, UCSD Torrey Pines Institute for Molecular Decky Goodrich* California Baptist University, College of La Jolla Bioengineering Institute San Diego Community College District Studies Donna Janson Engineering La Jolla Institute for Allergy & San Diego County Water Authority* UC San Diego Extension Elliot Parks California Medical Innovations Immunology San Diego Employers Association UCI’s Office of Research Gary Friedman Institute Lawrence Family Jewish Community San Diego Regional Chamber of UCSD, Department of Bioengineering John Kavanagh California State University, Fullerton* Center Commerce UCSD School of Medicine Julie Ames California State University, San Marcos Los Angeles Biomedical Research San Diego Regional Economic UCSD, Technology Transfer Office Mike Van Horn* Case Western Reserve, School of Institute Development Corp. UK Trade & Investment Peter Preuss Engineering MiraCosta College Biotech Program San Diego Supercomputer Center University of San Diego Richard Ledford CIRM Mt. San Jacinto College (UCSD) Stan Kim City Of Murietta PhRMA San Diego Workforce Partnership Tom Murphy* CONNECT Point Loma Nazarene University Sanford-Burnham Medical Research Consulate Of Canada PRISM* Institute CSU, CSUPERB Program Rady School of Management, UCSD Scottish Development International
32 Biocom LifeLines Fall 2015 Brizzey Green Charge Networks Occupational Services Thomas, McNerney & Partners KEY PROVIDER Caliber Associates Gunderson Dettmer Orion International Patent Office Time Warner Cable Barney & Barney California Commercial Security Hartl Team- Private Banking & Oxford Finance TriNet* Cushman & Wakefield Cambridge Research Biochemicals Investment Group- Merrill Lynch Pharmour Troutman Sanders* Foley & Lardner* CBRE Haworth PR Newswire TUV SUD America* Qualcomm Central Pharma Contract Packaging HCP Life Science Estates Prevost Construction Unanet San Diego Gas & Electric Chubb Group of Insurance Companies H.G. Fenton Company Procopio, Cory, Hargreaves & Savitch Unifirst Clinigen Healthcare Hyatt Regency La Jolla at Aventine Project Management Advisors United Parcel Service (UPS) Coastal Payroll Services Innovative Lease Services Prudential Cleanroom Services* Vault Bioventures PROVIDER Controlled Contamination Services J.T. MacMillan Photography Retirement DNA VDP Direct 2Connect Corning Jackson & Blanc HVAC Contractors Sartorius Veolia Accelrys CORT* Jones Lang LaSalle Savills Studley WCCT Global AER Travel Cox Business Kilroy Realty SecureDocs* AIS Data Centers CryoPort* Knobbe, Martens, Olson & Bear Scient Federal Credit Union Alexander’s Mobility Services CSM* Leadership Edge Sharp Business Systems Alliant Insurance Cymer Legacy Partners Commercial Sheppard Mullin Richter & Hampton AMN Healthcare Domain Associates Leverage Concierge* Shred San Diego Assay Depot DPR Construction* Life Science IT Signature Analytics Bank of America Elsevier Lonza AG Silicon Valley Bank Beckloff Associates EquipNet Managed Laboratory Services Sofinnova Ventures Bente Hansen & Associates Euretos Managed Solution Sonceboz Corporation Bionest Partners Ferguson Pape Baldwin Architects Mayer Hoffman McCann Speid & Associates BioSurplus Fisher & Phillips McKenna Long & Aldridge Springer Science & Business Media* Biotech Primer Forward Ventures Medline Industries Square 1 Bank Biotech Vending Fragomen, Del Rey, Bernsen & Loewy Michael Ehrenfeld Company* Stradling Yocca Carlson & Rauth Biotechnical Services* French Biobeach Morrison & Foerster Surplus Solutions BioTix Frequentz Newhoff Healthcare Communications Technical Safety Services Blue Sky Broadcast Grande Colonial Objective Capital Partners* The HealthEd Group * New Members from May 2015 to October 2015
HELPING INNOVATION THRIVE.
With more than 300 legal professionals operating in over 25 countries, our Life Sciences practice handles some of the most complex, high-profile life sciences transactions, litigation matters, patents and regulatory issues on behalf of biopharmaceutical and medical device companies. For five years in a row, DLA Piper has earned the No. 1 ranking globally for overall deal volume in Mergermarket’s league tables, and Global Corporate Venturing magazine has named us the 2015 Law Firm of the Year in Corporate Venture. We have built our reputation by providing cutting-edge solutions that help innovation thrive.
www.dlapiper.com
Lisa A. Haile, 4365 Executive Drive, Suite 1100, San Diego, CA 92121 | DLA Piper LLP (US) | Attorney Advertising SP13-4012 UNIVERSITY OFCALIFORNIA, SANDIEGO | EXTENSION Please sendachange ofaddress or subscriptionrequest toSonali Vittachi [email protected]. 10996 Torreyana Rd, Suite200 San Diego, CA92121-3021 www.Biocom.org (858) 534-9353| Explore our offerings, today! For yourconvenience,manyofourcoursesare offered online. Drug Discovery/ADMET • • Diagnostics ClinicalTrials • Business ofBiotech • Management Biotechnology Project • • Biostatistics Achieve your courses andcertificates tofi t yourcontinuing educationneeds. seeking high-levelskilldevelopment, UCSanDiegoExtensionhas Whether youarejustenteringtheLifeSciencesfield oryouare Life Sciences [email protected]| RegulatoryAffairs • Quality Assurance andControl • Medicinal Chemistry • Life SciencesIT/Bioinformatics • (Biofuels, Fermentation) Industrial Biotechnology • • Genomics extension.ucsd.edu/lifesciences educational goals!